- Regeneron’s monoclonal antibodies provide months of protection against COVID-19, CEO Len Schlieffer told CNBC on Monday.
- He added that they can be administered to individuals whose immune systems are not adequately protected by vaccines.
- Schlieffer’s comments came after data released by Regeneron indicated that its one-dose antibody cocktail reduced the risk of catching the virus by about 82% for two to eight months.
Regeneron’s monoclonal antibodies provide months of protection from COVID-19 and can be administered to individuals whose immune systems are not adequately shielded by vaccines, CEO Len Schlieffer told CNBC’s “Squawk Box” on Monday.
Schlieffer’s comments came after data released by Regeneron indicated that its one-dose antibody cocktail reduced the risk of catching the virus by about 82% for two to eight months. According to the Food and Drug Administration, monoclonals of Regeneron have been administered intravenously to treat moderate COVID symptoms during the pandemic and to reduce the likelihood of hospitalization in high-risk patients.
“If you want to protect people at the population level, vaccines are the best way to go — they’re cheap and you can make billions of doses,” Schlieffer said. “But our data now indicate that antibodies are the major players in the sense that they are sufficient.”
“You may not need cellular immunity. There may be some added to it, but based on these data the antibodies are enough to protect you from COVID-19,” he said.
Schlafer said, individuals with immunological conditions could eventually receive monoclonals of Regeneron every five or six months, “and they would be protected as if they had been vaccinated.” He said the treatment can be administered selectively to people who are at high risk for complications of COVID and there are concerns related to vaccination of essential workers.
But Schlieffer noted that he didn’t think Regeneron could produce enough antibodies at an affordable cost to be widely used as vaccines.
“If you’re in the military, or you’re a teacher or you’re on the front lines and you legitimately have this fear, maybe it could be offered as an option. It’s something we need to discuss.” It is,” Schlieffer said. “But the data – put politics aside – the data says antibodies can protect you from getting COVID-19.”
According to the FDA, Regeneron’s antibodies target the spike protein of COVID to prevent the virus from entering cells. The agency states that monoclonal antibodies “mimic the ability of the immune system to fight harmful pathogens.”
Regeneron isn’t the only company to have unveiled promising COVID treatment data in recent weeks. Pfizer announced Friday that its antiviral coronavirus pill can reduce the risk of hospitalization or death by 89% for high-risk adults after combining treatment with an HIV drug to help them last longer in the body. does it.
Merck and Ridgeback Biotherapeutics also released data on an antiviral pill in October that was said to cut hospitalizations and deaths of Covid by 50% for patients with mild or moderate cases.